All stock lists
Aktis Oncology, Inc. (NASDAQ:AKTS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
15.79+0.06 (+0.35%)
Insider Score
––Not scored
AKTS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AKTS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 3.38 M | 3.23 M | 1.87 M | 1.58 M | 1.60 M | 1.45 M |
| Revenue Growth (YoY) | 111.37 % | 123.01 % | 100.43 % | — | — | — |
| Cost of Revenue | 879.00 K | 652.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.50 M | 2.58 M | 1.87 M | 1.58 M | 1.60 M | 1.45 M |
| SG&A Expense | 6.12 M | 5.25 M | 2.51 M | 3.06 M | 3.68 M | 3.35 M |
| R&D Expense | 25.28 M | 20.04 M | 16.49 M | 16.47 M | 18.63 M | 15.86 M |
| Operating Expenses | 31.40 M | 25.28 M | 19.25 M | 19.78 M | 22.56 M | 19.59 M |
| Operating Income | -28.90 M | -22.71 M | -17.38 M | -18.20 M | -20.96 M | -18.14 M |
| Pretax Income | -24.14 M | -18.32 M | -15.14 M | -15.53 M | -18.07 M | -14.98 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -24.14 M | -18.32 M | -15.14 M | -15.53 M | -18.07 M | -14.98 M |
| EPS (Basic) | -0.44 | -0.33 | -0.28 | 0.00 | -0.34 | -0.43 |
| EPS (Diluted) | -0.44 | -0.33 | -0.28 | 0.00 | -0.34 | -0.43 |
| Shares Outstanding | 55.32 M | 55.28 M | 53.40 M | 0.00 | 52.52 M | 34.86 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.